Navigation Links
EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
Date:11/4/2007

m focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that the proposed public offering will not be consummated, the risks associated with our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not d
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. EpiCept Accelerates Development of Phase I Clinical Study for Cancer
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
3. Autopsy reports could be valuable and informative
4. China reports declining number of SARS Cases
5. Russia Reports First SARS Case
6. Research reports that c-section deliveries are rising
7. Jharkhand reports 13,000 Malaria cases
8. Uganda Reports Failure To Contain Sleeping Sickness
9. WHO reports 36 million deaths world wide due to chronic diseases
10. Reports of Hantavirus infection in India raise concerns
11. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Quintessa Medical Spa is happy to offer patients the latest treatment for ... the elimination of excess tissue under the chin, referred to as submental fat. ... offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by the ...
(Date:7/30/2015)... ... 30, 2015 , ... The New Jersey Innovation Institute (NJII), ... of Health, has received a $2.9 million grant from the Office of the ... Health and Human Services (HHS). NJII will help the Department of Health ensure ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Bird B ... a new bird hazing system to repel pest birds from the AC ... diseases—including histoplasmosis, encephalitis, salmonella, meningitis, and toxoplasmosis, even the West Nile virus. When these ...
(Date:7/30/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership solutions firm ... N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed his new ... Walsh is an expert in organizational change, physician development, implementation of quality and patient ...
(Date:7/30/2015)... Springfield, Mo (PRWEB) , ... July 30, 2015 , ... ... home health and hospice care, announced today that it is hosting a free webinar ... St. Pierre, RN, BSN, MGA, HEALTHCAREfirst Consultant and former Vice President of Regulatory Affairs ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2
... CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: ... published by the Seattle Times reporting ... incorrectly reported that CellCyte ,closes.,In CellCyte,s August 14, ... its bioreactor business segment and generally described its ...
... Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration on its,Abbreviated New Drug ... USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl,estradiol ...
... Priority ReviewEAST BRUNSWICK, N.J., Dec. 29 Savient ... announced that the U.S. Food and Drug Administration ... License Application (BLA) for pegloticase, a novel biological ... also granted the Company,s BLA with a priority ...
... Cross and Blue Shield of Oklahoma announced today the ... their next policy year. This change will not in ... always been available to children with autism. Blue Cross ... interests in the benefits and coverage of certain autism-related ...
... Dec. 29 Eastern Life & Health Insurance Company (ELH), ... EIHI ), announced today that it will add vision to ... include a vision insurance plan and a vision discount program, ... "Adding vision to ELH,s product portfolio enables employers to offer ...
... 29 Life for Relief and Development (LIFE), a ... the civilian victims of the recent conflict in Gaza. ... non-governmental organizations operating in the area, LIFE has obtained ... relief items to Gaza via a specially designated humanitarian ...
Cached Medicine News:Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 2Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 3Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 4Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 5Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 3Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 4Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
(Date:7/30/2015)... Calif. , July 30, 2015   ... to eliminate all preventable hospitalization, recently received confirmation ... its Remote Patient Intelligence (RPI) solution meets the ... FDA intends to exercise "Enforcement Discretion." ... not subject to further FDA regulatory requirements at ...
(Date:7/30/2015)... July 30, 2015  Lannett Company, Inc. (NYSE: ... at the Canaccord Genuity 35th Annual Growth Conference on ... the InterContinental Boston Hotel.  A webcast ... .  Listeners are encouraged to visit the web site ... the presentation to register, download and install any necessary ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
... YORK, June 20, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0558499/Top-Medical-Devices-and-Imaging-Technologies-2011.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices ... device and imaging technologies that have excellent ...
... VANCOUVER, British Columbia, June 17, 2011 Abattis Biologix Corporation ... commenced trading on the OTC Pink Sheets under the symbol ... the company proceeds with financing activities and the preparation of ... and other exchanges. Mike Withrow, CEO of Ab ...
Cached Medicine Technology:Reportlinker Adds Top Medical Devices and Imaging Technologies 2011 2Abattis Biologix Corporation Begins Trading on Pink Sheets 2
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: